During the course of the 2014 Genitourinary Cancers Symposium, The ASCO Post had the opportunity to speak with several of the world’s leading authorities about the state of the art in screening, diagnosis, and treatment for prostate and kidney cancers. In this second installment of a two-part report on genitourinary malignancies, we talk to David I. Quinn, MBBS, PhD, FRACP, Head of Genitourinary Medical Oncology at the USC Norris Comprehensive Cancer Center, Los Angeles, and Arie Belldefrun, MD, FACS, and Allan Pantuck, MD, MS, FACS, Professors of Urologic Oncology at the David Geffen School of Medicine at UCLA, about the present and future care of the patient with renal cell carcinoma.
Richard J. Boxer, MD, FACS, is Visiting Professor at the David Geffen School of Medicine at UCLA, Clinical Professor at the University of Wisconsin, Madison, and the Medical College of Wisconsin (Milwaukee), and former Professor of Clinical Urology at the University of Miami. He is also an Associate Editor of The ASCO Post.
Please describe current medical oncology approaches to first-line therapy for metastatic renal cell carcinoma.
The current first-line therapy for most patients with good- to intermediate-risk metastatic renal cell carcinoma is a vascular endothelial growth factor (VEGF)...
What is the role of immunotherapy in the treatment of metastatic renal cell carcinoma?
The harnessing of the immune system as an effective treatment for cancer was recently selected by the journal Science as the top scientific Breakthrough of the Year for 2013.1 With this...